Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy.
about
Regulation of mitochondrial functions by protein phosphorylation and dephosphorylationMyelodysplasia and myeloproliferative disorders in childhood: an update.Expression of interferon regulatory factor 1 and 2 in hematopoietic cells of children with juvenile myelomonocytic leukemia.Protein tyrosine phosphatases as potential therapeutic targets.Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.Protein Tyrosine Phosphatase SHP-2 (PTPN11) in Hematopoiesis and Leukemogenesis.Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant miceHuman somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignanciesIL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease.Quantitative effects of Nf1 inactivation on in vivo hematopoiesisDevelopment of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemiaTiming of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy.The GAP-related domain of neurofibromin attenuates proliferation and downregulates N- and K-Ras activation in Nf1-negative AML cells.Translational hematology.Gene expression of the hematopoietic cell phosphatase in juvenile myelomonocytic leukemia.Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group.Somatic PTPN11 mutations in childhood acute myeloid leukaemia.Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling.A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada.Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia
P2860
Q26752880-5FF8E984-0995-4CF8-8DDB-CB9F45ED8A0CQ33770597-DCF327B9-81EF-4456-9E37-12F9A40AE815Q33884620-61932358-4A62-44D4-9F4E-448887975DCCQ34295063-696B8606-46EA-4EBE-9E89-BC9FC37DB575Q34399676-1C70E1C6-88BE-4A24-9932-84D75020CA95Q35101627-D037B27C-13D6-4403-A68C-E45C2A973844Q35628894-7196FE59-210F-4E91-97E2-DC1D0873164BQ35847470-9EA78B4B-16CB-4EC0-8881-709C5A6F25FFQ35847802-4957AF28-3D47-4DEC-B603-CC816F3D2D5CQ35849015-BE45CD09-F554-4875-887D-216B9EB5C3A6Q36161397-85CADFAD-323C-42E2-B8FB-3088CE9B0A75Q36167910-C377C0BF-F510-4D5C-9F5A-167F2AE14698Q36407156-06776ED0-CA9C-47FC-998F-00FA6B3E3069Q36800462-9B553408-5C5C-4950-9C25-8529DBC2CE68Q37458231-0AC91F2C-EC08-4BE1-B0FD-11ABDAA887EFQ38247744-BD7BE5F8-32D5-4FCA-8494-3646F0085325Q40909825-2A0F3B05-EF44-46C6-A28E-8CC671406AD6Q44452165-98DCC6DD-8D44-45BB-8B09-82EA73B2BC9DQ45073102-0FB5A1EA-E46E-46B0-B02C-2B2BE0302BA7Q46447357-D0F25686-D377-45B4-9A06-ED938B20E4E0Q46863352-2E0D6CDF-955F-4A80-914A-5C69FE0684F1Q50652619-889A3A83-1B3D-4C15-97F3-2C67DCAA376FQ56008653-2A33CC78-5029-4DB9-A24A-668333BAB59D
P2860
Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy.
@en
type
label
Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy.
@en
prefLabel
Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy.
@en
P2093
P1476
Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy.
@en
P2093
Castleberry RP
Emanuel PD
Shannon KM
P304
P356
10.1016/1357-4310(96)10044-7
P577
1996-11-01T00:00:00Z